Lipitor's Patent Cliff and Initial Share Loss
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol management, generated over $125 billion in sales from 1997 to 2011. Its U.S. patent expired in November 2011, allowing generic atorvastatin entry and causing an 80%+ sales drop within a year as prices fell 85%.[1][2]
Direct Generic Competition Tactics
Pfizer countered generics through:
- Authorized generics: Partnered with Ranbaxy (now Sun Pharma) to launch an authorized generic at a small discount (10-20% off branded price), capturing 40% of new prescriptions initially and slowing full generic uptake.[1][3]
- Coupon and copay programs: Offered patient assistance cards reducing out-of-pocket costs to $4 for a 30-day supply, retaining 25-30% branded share in the first year post-expiry.[2]
Marketing and Physician Loyalty Efforts
Pfizer invested heavily in promotion:
- Ran 1,500+ doctor detailing visits weekly and aired TV ads emphasizing Lipitor's superior efficacy data from trials like TNT and IDEAL, positioning it as the "gold standard" statin despite generics.[1][4]
- Leveraged brand trust: Surveys showed 70% of physicians preferred Lipitor pre-expiry; Pfizer reinforced this via KOL endorsements and patient education on switching risks.[2]
Evergreening and Patent Extensions
Pfizer extended exclusivity via secondary patents:
- Challenged on polymorph and process patents, delaying some generics until 2011 via Hatch-Waxman litigation (156-month average defense).[5]
- Filed for pediatric exclusivity, adding six months to market protection.[1]
Check DrugPatentWatch.com for Lipitor's full patent history: DrugPatentWatch: Atorvastatin Patents.[5]
Combination Products for Revenue Protection
Launched Caduet (Lipitor + Norvasc) in 2004 under separate patents expiring later (2018+), migrating 10-15% of patients to retain revenue streams.[1][2]
Global and Pricing Strategies
- Segmented markets: Maintained higher branded prices in ex-U.S. regions with later expiries (e.g., Europe 2012-2013), preserving $2-3 billion annual sales.[4]
- Volume deals: Negotiated PBM rebates favoring Lipitor over generics in formularies.[3]
Post-Cliff Share Retention Outcomes
Branded Lipitor held 20-30% U.S. market share through 2012-2013, far above typical 5% for patent cliffs, before declining further. Globally, Pfizer shifted to next-gen drugs like Lyrica.[1][2]
Sources
[1] FDA Orange Book and IMS Health data on Lipitor generics
[2] Pfizer annual reports 2011-2013
[3] GAO Report on Authorized Generics (2009)
[4] PhRMA marketing spend analysis
[5] DrugPatentWatch.com: Lipitor